Gain of heterozygosity: an embryo-only, single-nucleotide polymorphism-based method to identify meiotic trisomies in preimplantation genetic testing for aneuploidy
Reproductive BioMedicine Online · 2026
DOI: 10.1016/j.rbmo.2026.105704 ↗Kurz gefasst
Fachartikel in der Zeitschrift Reproductive BioMedicine Online, 2026. Verfasst von Miroslav Hornak und 6 weiteren Autor:innen. Beteiligte Einrichtung: REPROMEDA Biology Park, Studentska 812/6, 625 00 Brno, Czech Republic. Electronic address: mhornak@repromeda.cz. Hauptthemen laut MEDLINE: Polymorphism, Single Nucleotide, Preimplantation Diagnosis, Aneuploidy, Trisomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
RESEARCH QUESTION: Can gain of heterozygosity (GOH) measured from embryo single- nucleotide polymorphism (SNP) data reliably identify meiotic trisomies during PGT-A without parental DNA samples? DESIGN: Retrospective single-centre laboratory study using de-identified trophectoderm biopsy data from a combined monogenic disorder and aneuploidy testing programme. After whole-genome amplification and SNP-array genotyping, chromosomes were divided into bins of approximately 150 heterozygous markers using a euploid reference panel. The GOH was calculated as the relative increase in heterozygosity per bin; bins with 30% or more gain were considered GOH-positive, and chromosomes with three or more consecutive GOH-positive bins were classified as meiotic trisomies. Meiotic origin was verified by parental haplotype analysis (karyomapping). RESULTS: Among 209 meiotic trisomies (205 evaluable), GOH algorithm correctly classified 200, yielding a sensitivity of 97.6%. Misclassifications occurred mainly on small chromosomes with limited GOH coverage; one occurred in an embryo from a consanguineous union with reduced heterozygosity. In the clinical cohort of 1261 blastocysts (301 IVF cycles; mean maternal age 34.2 years), 63.6% were euploid, 29.9% uniformly aneuploid and 6.5% mosaic. The GOH analysis identified 200 meiotic trisomies and five meiotic triploids. The GOH-positive regions showed a 45.6% increase in heterozygous SNPs compared with diploid baseline, and spanned, on average, 74.1% of the trisomic chromosome length. Among 410 chromosome-error events, 89% arose from maternal meiosis; in mosaic embryos, parental contributions were balanced. CONCLUSIONS: GOH provides an embryo-only, SNP-based method to classify trisomies (meiotic versus mitotic) as an add-on to standard copy number variations/B-allele frequency assessment, without requiring parental DNA. This added mechanistic resolution may reduce clinically relevant misclassification of trisomies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- REPROMEDA Biology Park, Studentska 812/6, 625 00 Brno, Czech Republic. Electronic address: mhornak@repromeda.cz.
- REPROMEDA Biology Park, Studentska 812/6, 625 00 Brno, Czech Republic.
Zitieren
APA
Hornak, M., Brozek, R., Musilova, P., Navratil, R., Kubicek, D., Travnik, P., & Vesela, K. (2026). Gain of heterozygosity: an embryo-only, single-nucleotide polymorphism-based method to identify meiotic trisomies in preimplantation genetic testing for aneuploidy. Reproductive BioMedicine Online. https://doi.org/10.1016/j.rbmo.2026.105704
Vancouver
Hornak M, Brozek R, Musilova P, Navratil R, Kubicek D, Travnik P, et al. Gain of heterozygosity: an embryo-only, single-nucleotide polymorphism-based method to identify meiotic trisomies in preimplantation genetic testing for aneuploidy. Reproductive BioMedicine Online. 2026. doi:10.1016/j.rbmo.2026.105704
BibTeX
@article{Hornak2026,
author = {Hornak, Miroslav and Brozek, Radim and Musilova, Petra and Navratil, Rostislav and Kubicek, David and Travnik, Pavel and Vesela, Katerina},
title = {Gain of heterozygosity: an embryo-only, single-nucleotide polymorphism-based method to identify meiotic trisomies in preimplantation genetic testing for aneuploidy},
journal = {Reproductive BioMedicine Online},
year = {2026},
doi = {10.1016/j.rbmo.2026.105704}
}
EUVIMED